Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Buffered formulations of exendin (9-39)

Buffered formulations of exendin (9-39)

US Patent 11020484 · Granted Jun 1, 2021

Estimated economic value: $4,089,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39)2025
Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39)2025
Treatment of post-bariatric hypoglycemia with exendin (9-39)2024
Treatment of post-bariatric hypoglycemia with exendin (9-39)2024
Methods of using buffered formulations of exendin (9-39)2023
Methods of using buffered formulations of exendin (9-39)2023
Methods of using buffered formulations of exendin (9-39)2023
Methods of using buffered formulations of exendin (9-39)2023
Methods of using buffered formulations of exendin (9-39)2023
Treatment of post-bariatric hypoglycemia with GLP-1 antagonists2023
Treatment of post-bariatric hypoglycemia with GLP-1 antagonists2023
Treatment of post-bariatric hypoglycemia with exendin (9-39)2023